<DOC>
	<DOCNO>NCT02674308</DOCNO>
	<brief_summary>The purpose study ass long-term safety vedolizumab versus biologic agent participant Ulcerative Colitis ( UC ) Crohn 's Disease ( CD ) .</brief_summary>
	<brief_title>Entyvio ( Vedolizumab ) Long Term Safety Study</brief_title>
	<detailed_description>The drug test prospective , observational study call vedolizumab . Vedolizumab use treat people UC CD . This study look long-term safety vedolizumab versus biologic agent participant UC CD . The study enroll approximately 5000 participant . All participant enrol belong one two treatment group : - Vedolizumab - Other Biologic Agents -adalimumab , certolizumab pegol . Golimumab infliximab . Study drug prescribe physician accord local prescribing information participate country . This multi-centre trial conduct worldwide . The overall time participate study 7 year . Participants make visit every 6 month treat physician .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Signed informed consent , participant legally acceptable representative . 2 . Aged least 18 year . 3 . Initiating vedolizumab another biologic agent UC CD . 4 . Signed release form , participant legally acceptable representative , permit abstraction participant 's medical record Baseline participation study . 1 . The participant enrol clinical trial treatment CD UC manage protocol . 2 . Prior treatment vedolizumab . 3 . Any reason , Investigator 's opinion , make participant unsuitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>